Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Cingulate Inc (CING)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CING (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -65.14% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.98M USD | Price to earnings Ratio - | 1Y Target Price 25.5 |
Price to earnings Ratio - | 1Y Target Price 25.5 | ||
Volume (30-day avg) 88704 | Beta -0.84 | 52 Weeks Range 1.80 - 20.83 | Updated Date 04/1/2025 |
52 Weeks Range 1.80 - 20.83 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.84 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -104.33% | Return on Equity (TTM) -273.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5769511 | Price to Sales(TTM) - |
Enterprise Value 5769511 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.36 | Shares Outstanding 3647660 | Shares Floating 3203367 |
Shares Outstanding 3647660 | Shares Floating 3203367 | ||
Percent Insiders 3.3 | Percent Institutions 2.82 |
Analyst Ratings
Rating 4.5 | Target Price 48.33 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cingulate Inc
Company Overview
History and Background
Cingulate Inc. is a biopharmaceutical company focused on developing and commercializing novel therapeutics for attention deficit hyperactivity disorder (ADHD). Founded in 2013, Cingulate's primary focus is on developing differentiated treatments designed to improve the lives of patients with ADHD.
Core Business Areas
- ADHD Therapeutics Development: Focuses on research, development, and commercialization of novel ADHD medications.
Leadership and Structure
The leadership team consists of seasoned pharmaceutical executives and scientists with experience in drug development and commercialization. The company has a typical biopharmaceutical organizational structure with departments focused on research, clinical development, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- CTX-1301 (dexmethylphenidate): An oral, immediate-release tablet formulation of dexmethylphenidate. Currently in development. Competitors include branded and generic versions of methylphenidate and dexmethylphenidate (e.g., Ritalin, Focalin).
- CTX-1302 (dextroamphetamine): An oral, immediate-release tablet formulation of dextroamphetamine. Currently in development. Competitors include branded and generic versions of amphetamine and dextroamphetamine (e.g., Adderall).
Market Dynamics
Industry Overview
The ADHD therapeutics market is a significant and growing market, driven by increasing diagnosis rates, rising awareness, and the availability of effective treatments. The market includes stimulants (methylphenidate and amphetamine-based drugs) and non-stimulants.
Positioning
Cingulate is positioned as a developer of differentiated ADHD medications designed to improve patient outcomes and address unmet needs in the ADHD market.
Total Addressable Market (TAM)
The ADHD market is estimated to be in the billions of dollars annually. Cingulate aims to capture a portion of this market with its novel drug candidates.
Upturn SWOT Analysis
Strengths
- Novel drug candidates with potential for improved efficacy and safety profiles
- Experienced leadership team
- Focus on a large and growing market
- Intellectual property protection for its drug candidates
Weaknesses
- Clinical trial risk (drug may not prove to be effective)
- Regulatory approval risk (drug may not be approved by the FDA)
- Commercialization risk (drug may not be successfully launched and marketed)
- Financial risk (the company requires significant capital to fund its operations)
- Limited operating history
Opportunities
- Potential to capture significant market share with successful drug launches
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Increasing awareness and diagnosis rates of ADHD
Threats
- Competition from established pharmaceutical companies
- Generic competition
- Changes in regulatory landscape
- Economic downturn
- Negative clinical trial results
Competitors and Market Share
Key Competitors
- Takeda Pharmaceutical Company Limited (TAK)
- Supernus Pharmaceuticals, Inc. (SUPN)
- Johnson & Johnson (JNJ)
Competitive Landscape
Cingulate faces significant competition from established pharmaceutical companies with existing ADHD medications. Its competitive advantage lies in its novel drug candidates and potential for improved efficacy and safety profiles.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: As a development-stage company, historical growth is limited to progress in its clinical programs.
Future Projections: Future growth is dependent on the successful development and commercialization of its drug candidates. Analyst estimates vary and are subject to change based on clinical trial results and regulatory developments.
Recent Initiatives: Recent initiatives include advancing its clinical programs for CTX-1301 and CTX-1302.
Summary
Cingulate Inc is a development-stage biopharmaceutical company focused on ADHD. The company needs to obtain successful clinical trial outcomes and regulatory approvals. Cingulate is a high-risk, high-reward investment. The market has significant players, so competition is stiff.
Similar Companies
- TAK
- SUPN
- JNJ
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a financial professional. Market share data is an estimate and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cingulate Inc
Exchange NASDAQ | Headquaters Kansas City, KS, United States | ||
IPO Launch date 2021-12-08 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.cingulate.com |
Full time employees 13 | Website https://www.cingulate.com | ||
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.